Abstract
Mutated anaplastic lymphoma kinase (ALK) drives the development of multiple tumor types, and ALK tyrosine kinase inhibitors such as crizotinib have been validated as targeted therapeutics. Unfortunately, as with other oncogene-driven tumors, therapeutic resistance invariably develops. In Science Translational Medicine, two recent studies provide new insight into mechanisms of resistance to ALK tyrosine kinase inhibitors and possible strategies to overcome this resistance.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Anaplastic Lymphoma Kinase
-
Crizotinib
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics*
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrazoles / therapeutic use*
-
Pyridines / therapeutic use*
-
Receptor Protein-Tyrosine Kinases / genetics*
-
Receptor Protein-Tyrosine Kinases / metabolism*
Substances
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyridines
-
Crizotinib
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases